Previous studies have shown that HER2 low expression (IHC2+/FISH−) exceeds 40–60% of GC patients, but no HER2-targeted ADC drugs are authorized up to now (Moelans et al., 2011). The gene discussed is ERBB2; the disease is gastric cancer.